GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Emcure Pharmaceuticals Ltd

Emcure Pharma reaffirms 'CARE AA; Stable' credit ratings

RATING ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 01 Sep 2026, 03:44 PM IST  ·  BSE ID: 69b7427c-1084-45a1-9475-c8748cb67bad
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's credit score remained strong, reflecting good financial health and business performance.
🤖 AI Summary
  • Emcure Pharmaceuticals' bank facilities reaffirmed with 'CARE AA; Stable' rating.
  • Company reported Rs. 9,322 crore revenue in FY26, an 18% year-on-year growth.
  • PBILDT margin improved to 20.0% in FY26 from 18.7% in FY25.
  • Ratings acknowledge strategic partnerships and acquisition of Gennova Biopharmaceuticals stake.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Long-term bank facilities
785.00 Rs. Crore
Long-term / Short-term bank facilities
1,563.00 Rs. Crore
Short-term bank facilities
52.00 Rs. Crore
FY26 Revenue
~₹9,322 crore
~18%
FY26 PBILDT margin
20.0%
FY25 PBILDT margin
18.7%
Gennova Biopharmaceuticals stake acquisition cost
~₹232 crore
mRNA business divestment consideration
~₹140 crore
🏢 How This Affects the Company
📈
Business Impact
The reaffirmation of credit ratings supports Emcure's access to funding for business growth and strategic initiatives.
💰
Financial Impact
Improved PBILDT margins to 20.0% indicate enhanced operational efficiency and profitability.
⚙️
Operational Impact
Strategic partnerships and focus on differentiated products, including in complex injectables, signal ongoing operational development.
⚠️
Risk Impact
Ratings are constrained by inherent industry regulatory risks and foreign exchange fluctuations, which remain ongoing considerations.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders regarding this credit rating update.
👤
Who Is Affected
All shareholders are indirectly affected by the company's stable credit profile, which influences borrowing costs and financial flexibility.
🔍
Management Signal
Management continues to focus on strategic growth initiatives and profitability enhancement, as reflected in rating reaffirmations.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
FY27 Q1 results for revenue and margin trends.
Update on strategic partnerships and product pipeline progress.
Future debt levels and capital structure management.
MEDIUM RISK Ratings factors in inherent industry regulatory risks and forex fluctuations.
💡 Investor Takeaway
Emcure Pharmaceuticals reaffirms 'CARE AA; Stable' ratings. FY26 revenue reached Rs. 9,322 crore (18% YoY growth), with PBILDT margin at 20.0%.
⚖️ Strengths & Concerns

✅ Positives

  • FY26 revenue grew 18% to Rs. 9,322 crore, driven by strong international market performance.
  • PBILDT margin increased to 20.0% in FY26 from 18.7% in FY25, showing improved profitability.

⚠️ Concerns

  • Inherent regulatory risks in global pharmaceutical markets remain a constraint on ratings.
  • Exposure to foreign exchange fluctuations is a continued factor impacting financial performance.
❓ Frequently Asked Questions
What credit rating has CARE Ratings reaffirmed for Emcure Pharmaceuticals?
CARE Ratings has reaffirmed the 'CARE AA; Stable' rating for Emcure Pharmaceuticals' bank facilities.
What was Emcure Pharmaceuticals' revenue in FY26?
Emcure Pharmaceuticals reported revenue of approximately ₹9,322 crore in FY26.
How much did Emcure Pharmaceuticals' revenue grow year-on-year in FY26?
Emcure Pharmaceuticals' revenue registered a year-on-year growth of approximately 18% in FY26.
What was Emcure Pharmaceuticals' PBILDT margin in FY26?
Emcure Pharmaceuticals' PBILDT margin increased to 20.0% in FY26 from 18.7% in FY25.
What was the value of Emcure Pharmaceuticals' acquisition of additional stake in Gennova Biopharmaceuticals?
Emcure Pharmaceuticals acquired an additional 12.05% stake in Gennova Biopharmaceuticals for approximately ₹232 crore.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.